Long-Term BoNT-A Therapy Compliance Low Among Men

Share this content:
Only a quarter of men receiving injections of BoNT-A comply with the treatment long-term.
Only a quarter of men receiving injections of BoNT-A comply with the treatment long-term.

Intravesical injections of botulinum toxin A (BoNT-A) can be an effective treatment for men with overactive bladder (OAB) symptoms, but only a quarter of men comply with the treatment long term, according to a single-center retrospective study.

Mohammad S. Rahnama'I, MD, of Zuyderland Medical Centre in Heerlen, The Netherlands, and colleagues evaluated a heterogeneous group of 88 male patients with OAB treated with BoNT-A (100–300 U). The mean follow-up was 69 months.

Twenty-two patients (25%) continued BoNT-A treatment at last follow-up, the investigators reported in a paper published online ahead of print in Neurourology and Urodynamics. Of those who discontinued treatment, 35 had insufficient effect and 27 had tolerability issues. Four patients stopped treatment for reasons unrelated to BoNT-A. During follow-up, 24% of the study population had to use intermittent catheterization (de novo) or indwelling catheters at some point.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters